Mariner LLC Has $352,000 Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

Mariner LLC trimmed its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 7.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,039 shares of the company’s stock after selling 689 shares during the period. Mariner LLC’s holdings in Revolution Medicines were worth $352,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in RVMD. Barclays PLC raised its position in Revolution Medicines by 187.1% during the third quarter. Barclays PLC now owns 294,664 shares of the company’s stock valued at $13,362,000 after purchasing an additional 192,021 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Revolution Medicines during the 3rd quarter worth $801,000. Everence Capital Management Inc. bought a new stake in shares of Revolution Medicines during the 4th quarter worth $203,000. Avanza Fonder AB acquired a new stake in Revolution Medicines in the fourth quarter valued at about $173,000. Finally, Sandy Cove Advisors LLC bought a new position in Revolution Medicines in the fourth quarter valued at about $1,837,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Revolution Medicines news, CFO Jack Anders sold 1,864 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the transaction, the chief financial officer now directly owns 115,006 shares in the company, valued at approximately $4,489,834.24. This represents a 1.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark A. Goldsmith sold 11,738 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the sale, the insider now owns 441,564 shares of the company’s stock, valued at $17,238,658.56. This represents a 2.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,660 shares of company stock valued at $650,406 in the last ninety days. 8.00% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $59.00 price target on shares of Revolution Medicines in a research note on Tuesday, April 8th. Stifel Nicolaus cut their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Wedbush reiterated an “outperform” rating and set a $67.00 price target on shares of Revolution Medicines in a report on Monday, April 28th. UBS Group raised their price objective on Revolution Medicines from $65.00 to $71.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright upped their target price on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $66.67.

Revolution Medicines Stock Performance

Revolution Medicines stock opened at $40.72 on Friday. The firm has a market cap of $7.58 billion, a price-to-earnings ratio of -11.34 and a beta of 1.11. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $62.40. The firm has a 50 day moving average price of $37.34 and a two-hundred day moving average price of $43.74.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). As a group, equities research analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.